REGENXBIO prices upsized public offering of common stock and pre-funded warrants at $23.00 per share

REGENXBIO Inc.

Offering includes 4,565,260 shares at $23.00 and 1,521,740 pre-funded warrants at $22.9999, with gross proceeds ~$140M.
Net proceeds expected ~$131.2M (or $150.9M if underwriters fully exercise 30-day option for 913,050 additional shares).
Underwriters include Morgan Stanley, Goldman Sachs, Barclays, and Stifel as joint book-running managers.
Pre-funded warrants have $0.0001 exercise price, are exercisable immediately, and do not expire.
Offering expected to close March 11, 2024, under shelf registration statement (File No. 333-269086).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.